China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class ASZSE: 300294

China Resources Boya Bio-pharmaceutical Group: Net profit up 10.2% to RMB5.54 billion on 4.7% revenue growth; interim dividend declared

· Issued by China Resources Boya Bio-pharmaceutical Group Co., Ltd. Class A

Revenue grew 4.7% to RMB128.60 billion and net profit rose 10.2% to RMB5.54 billion in 1H2024, with strong performance in manufacturing, digital transformation, and green initiatives. Interim dividend declared for the first time.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.